Abstract: In a meta-analysis of 8 randomized controlled
trials including obese patients with Type 2 diabetes, the addition of sibutramine to standard diabetes therapy resulted in a significant decrease in body weight and hemoglobin A1c.
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.